Study Reveals Racial Disparities in Acute Care Utilization Among Patients With Myasthenia Gravis


Recent research, presented at the 2023 AANEM Annual Meeting, emphasized the potential need for patient support programs targeting at-risk populations to enhance disease management and reduce acute care utilization in myasthenia gravis.

Glenn Phillips, PhD, the senior director of Health Economics & Outcomes Research at Argenx

Glenn Phillips, PhD

A new retrospective cohort study revealed significant differences in acute care utilization, including emergency department (ED) visits and hospitalizations, among different racial subgroups of patients with myasthenia gravis (MG).1 These findings highlight the need to identify and address factors that contribute to these disparities and to ensure that all patients receive equitable and effective treatment.

Among 7058 patients with MG, investigators observed significant differences in age, gender, geographic region, insurance status, and rates of hyperlipidemia, thyroid-related disorders, gastroesophageal reflux disease, anxiety, depression, and thymoma among racial subgroups. After adjusting for baseline characteristics using a multivariable model, nonHispanic Black patients had a 37% increased odds of experiencing an ED visit compared with nonHispanic Caucasian patients (P = .04) in year 1. Nobably, Hispanic patients had a 70% increased odds of hospitalization compared with nonHispanic Caucasian patients (P = .04) in year 2.

Clinical Takeaways

  • Racial disparities exist in the acute care utilization of patients with myasthenia gravis, with nonHispanic Black and Hispanic patients experiencing higher odds of ED visits and hospitalizations.
  • Patient support programs may be a potential solution to reduce the burden of acute care utilization and improve disease management for patients with MG.
  • Early intervention and further research are needed to better understand the factors contributing to disparities in care among patients with MG of different racial backgrounds.

"This study provided evidence of potential racial disparities in care among those with MG, but further research is needed to characterize factors related to increased acute care utilization,"senior author Glenn Phillips, PhD, the senior director of Health Economics & Outcomes Research at Argenx, and colleagues wrote.1 "Our findings also indicate that certain factors may be important early after diagnosis, while others may not. Acute care events represent a high burden for payers, hospitals and most importantly, patients. Patient support programs targeted towards at-risk populations may have the potential to improve disease management and reduce acute care utilization."

READ MORE: Efgartigimod Shows Consistent Safety Profile Across Immunoglobulin G-Mediated Autoimmune Diseases in Trials

Presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting, held November 1-4, in Phoenix, Arizona, this study used Optum’s deidentified Market Clarity Data between 2010 and 2019 to evaluate acute care utilization, including ED visits and hospitalizations, in patients with newly diagnosed MG. Using multivariable logistic regression models, investigators assessed differences in outcomes in year 1 and year 2 post-diagnosis between racial subgroups, which included patients who identified as nonHispanic Caucasian, Black and Asian, and Hispanic.

In a previous retrospective analysis published in 2015, findings further confirmed the existence of ethnicity-based differences in clinical and laboratory features of MG.2 A total of 44 patients were included, including 19 Hispanic, 16 African American, 6 Caucasian, and 3 of Asian ethnicity. Results showed that anti-acetylcholine receptor antibody subtypes had no significant ethnicity-based differences regardless of either generalized or occular MG.

Additional findings from that analysis showed a trend toward greater frequency of blocking antibodies among Hispanic patients (52.6%) compared with African American (37.5%) and Caucasian (33.3%) patients (P = .059). Generalized but not ocular MG in patients showed a greater frequency of antimuscle-specific kinase antibodies among Asian and Hispanic patients compared with those of African American and Caucasian descent(P = .041). The researchers noted that further investigations of genetic factors influencing clinical features of MG are important to enhance understanding of the disease.

Click here for more coverage on AANEM 2023.

1. Qi C, Anderson A, Gelinas D, et al. Racial Disparities in Acute Care Utilization Outcomes Among Those with Myasthenia Gravis. Presented at: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting; November 1-4, 2023; Phoenix, AZ. Abstract 25.
2. Abukhalil F, Mehta B, Saito E, Mehta S, McMurtray A. Gender and Ethnicity Based Differences in Clinical and Laboratory Features of Myasthenia Gravis. Autoimmune Dis. 2015;2015:197893. doi:10.1155/2015/197893
Related Videos
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
Michael Kaplitt, MD, PhD
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.